 Glucagon-Like Peptide-2 Receptor
"Glucagon-Like Peptide-2 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor for GLUCAGON-LIKE PEPTIDE 2 (GLP-2) that is expressed on the surface of intestinal cells as well as neural cells. GLP-2 and other peptides act through GLP-2R to regulate cellular responses to BLOOD GLUCOSE, INFLAMMATION, and FOOD INTAKE.
| Descriptor ID |
D000067758
|
| MeSH Number(s) |
D12.776.543.750.695.021.600 D12.776.543.750.750.360.100.600
|
| Concept/Terms |
Glucagon-Like Peptide-2 Receptor- Glucagon-Like Peptide-2 Receptor
- Peptide-2 Receptor, Glucagon-Like
- Receptor, Glucagon-Like Peptide-2
- GLP-2 Receptor
- GLP 2 Receptor
- Receptor, GLP-2
- GLP2R Protein
- Protein, GLP2R
- Glucagon-Like Peptide 2 Receptor
- Glucagon Like Peptide 2 Receptor
- GLP-2R Receptor
- GLP 2R Receptor
- Receptor, GLP-2R
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-2 Receptor".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-2 Receptor".
This graph shows the total number of publications written about "Glucagon-Like Peptide-2 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-2 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2024 | 0 | 2 | 2 | | 2025 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide-2 Receptor" by people in Profiles.
-
Shah VN, Dex T, Meneghini L, Rodrigues A, Polonsky WH. Treatment satisfaction and time in range after 16?weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 May; 27(5):2523-2530.
-
Fr?as JP, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah VN. Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 Apr; 27(4):2173-2182.
-
Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Jan; 27(1):1-9.
-
Zeitler P, Galindo RJ, Davies MJ, Bergman BK, Thieu VT, Nicolay C, Allen S, Heine RJ, Lee CJ. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care. 2024 Jun 01; 47(6):1056-1064.
-
Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 Jun; 26(6):367-374.
-
Panaro BL, Yusta B, Matthews D, Koehler JA, Song Y, Sandoval DA, Drucker DJ. Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. Mol Metab. 2020 07; 37:100990.
-
Wismann P, Barkholt P, Secher T, Vrang N, Hansen HB, Jeppesen PB, Baggio LL, Koehler JA, Drucker DJ, Sandoval DA, Jelsing J. The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. Mol Metab. 2017 07; 6(7):681-692.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|